# Plasma metabolite markers for 13 cancers (Beijing Friendship Hospital)

Source: https://onco.cc/trials/beijing-metabolomics-multi-cancer/  
OnCo record `beijing-metabolomics-multi-cancer` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Chinese study looking for small molecules in blood that could flag 13 different cancers.

## Summary

Plasma metabolite markers for 13 cancers (NCT06363123) is an observational study sponsored by Beijing Friendship Hospital. It builds a plasma metabolite database for several cancers and develops and validates metabolic markers for early diagnosis.

The registry record, read on 29 October 2026, gives its status as unknown (the sponsor last updated it on 15 April 2024), with an estimated 2,700 participants, a start on 29 March 2024 and primary completion expected in October 2024.

## Fields

- Kind: Trial
- Last checked: 2026-10-29
- Registry id: NCT06363123
- Phase: observational
- Setting: People with one of 13 cancers and controls at four Chinese centres, profiled by mass spectrometry
- Sponsor: Beijing Friendship Hospital
- Enrolled: 2700

## Sources

- ClinicalTrials.gov NCT06363123: https://clinicaltrials.gov/study/NCT06363123

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)

---
JSON: https://onco.cc/api/v1/entities/beijing-metabolomics-multi-cancer.json